---
schema_version: "secwatch.filing_event.v1"
accession: "0001641172-25-002009"
form_type: "8-K"
ticker: "RNXT"
cik: "0001574094"
company_name: "RenovoRx, Inc."
filed_at: "2025-04-01T23:59:59+00:00"
generated_at: "2026-05-24T00:47:43.188272+00:00"
event_type: "earnings"
sentiment: "positive"
materiality_score: 0.65
calibrated_materiality_score: 0.65
confidence: "high"
source: SEC EDGAR
---

# RenovoRx reports first RenovoCath revenue of $43k in Q4 2024; TIGeR-PaC trial 79% enrolled

## Summary
- First commercial RenovoCath revenue ~$43k in Q4 2024; sequential growth expected in 2025.
- TIGeR-PaC trial: 90 of 114 patients randomized; 50 of 86 events; 2nd interim analysis at 52nd event expected Q2 2025.
- Cash $7.2M at 2024 year-end; $10.9M net raised in Feb 2025 public offering.
- Net loss $8.8M in 2024 vs $10.2M in 2023; R&D $6.0M, SG&A $5.0M.
- Shares outstanding 36.5M as of March 25, 2025.

## SEC filing metadata
- accession: 0001641172-25-002009
- form_type: 8-K
- ticker: RNXT
- cik: 0001574094
- company_name: RenovoRx, Inc.
- filed_at: 2025-04-01T23:59:59+00:00
- event_type: earnings
- sentiment: positive
- materiality_score: 0.65
- calibrated_materiality_score: 0.65
- confidence: high
- sec_items: 2.02, 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1574094/000164117225002009/0001641172-25-002009-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1574094/000164117225002009/form8-k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001641172-25-002009
- JSON: https://secwatch.observer/filing/0001641172-25-002009.json
- Plain text: https://secwatch.observer/filing/0001641172-25-002009.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.